Research programme: apolipoprotein A1 - BioDelivery SciencesAlternative Names: Apolipoprotein A1 research programme - BioDelivery Sciences
Latest Information Update: 11 Apr 2007
At a glance
- Originator BioDelivery Sciences International
- Mechanism of Action Apolipoprotein A I stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 20 Apr 2004 Preclinical trials in Atherosclerosis in USA (PO)